THE NEXT STEP IN OUTBREAK INVESTIGATIONS
Healthcare-associated infections (HAIs) affect 4-5% of hospitalized patients in the U.S. and result in 99,000 deaths per year. The rising prevalence of multi-drug resistant organisms has made HAIs particularly dangerous, and has increased the need for rapid, effective interventions to control an outbreak.
Day Zero Diagnostics introduces the precision and clarity of whole genome sequencing to outbreak investigations with epiXact® (pronounced epi-zact). The epiXact service provides definitive determination of pathogen relatedness in a suspected outbreak in less than 2 days. Sequencing and analysis are performed by experts using single-nucleotide polymorphism (SNP) comparisons of the whole genome, offering superior resolution to traditional techniques such as molecular strain typing or PFGE.
Outbreak Investigations involve high stake decisions. Our rapid response service gives infection control teams the confidence to act quickly when an outbreak is real and to call off unnecessary and expensive interventions when they can be ruled out.
epiXact Confirms a Transmission in a Clinical Trial with Wide Ranging Implications
Using epiXact to Determine if Large Scale Healthcare Worker Screening for MRSA is Merited
RESEARCH USE ONLY, NOT FOR USE IN DIAGNOSTIC PROCEDURES